Structured evidence table for Potassium Blood Pressure Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Potassium Blood Pressure Randomized Trial | In LMICs, limited healthcare access, socioeconomic constraints, medication costs, and insufficient familiarity with guideline-based management further exacerbate poor BP control. | 3 | Park Jong Seon (2026) | From concept to clinical practice: the evolution of low- and ultra-low-dose triple combination therapy for hypertension |
| Potassium Blood Pressure Randomized Trial | Earlier achievement of BP targets may reduce cumulative CV risk and prevent long-term structural damage associated with sustained hypertension []. | 3 | Park Jong Seon (2026) | From concept to clinical practice: the evolution of low- and ultra-low-dose triple combination therapy for hypertension |
| Potassium Blood Pressure Randomized Trial | Importantly, these early studies did not use all agents at low doses; rather, they typically employed a reduced dose of a specific component—most often a diuretic—while maintaining standard doses of the other agents. | 3 | Park Jong Seon (2026) | From concept to clinical practice: the evolution of low- and ultra-low-dose triple combination therapy for hypertension |
| Potassium Blood Pressure Randomized Trial | 1 2 Hypertension remains one of the most significant global public health challenges, accounting for an estimated 10 million deaths annually and contributing substantially to cardiovascular (CV) morbidity and mortality []. | 3 | Park Jong Seon (2026) | From concept to clinical practice: the evolution of low- and ultra-low-dose triple combination therapy for hypertension |
| Potassium Blood Pressure Randomized Trial | A well-known adverse event, hyperkalemia, is associated with fatal arrhythmia and discontinuation of MRA. | 4 | Hirai T (2026) | Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: Clinical Evidence, Pharmacology, and Drug-Drug Interactions for Personalized Management of Hyperkalemia. |
| Potassium Blood Pressure Randomized Trial | Cytochrome P450 3A4 (CYP3A4) inhibitors are pharmacokinetic precipitators that interact with most MRAs, except spironolactone, and adversely affect the risk of hyperkalemia, although suggestive evidence is scarce. | 4 | Hirai T (2026) | Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: Clinical Evidence, Pharmacology, and Drug-Drug Interactions for Personalized Management of Hyperkalemia. |
| Potassium Blood Pressure Randomized Trial | Individualized interventions for hyperkalemia risk are important in treatment using MRA. | 4 | Hirai T (2026) | Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: Clinical Evidence, Pharmacology, and Drug-Drug Interactions for Personalized Management of Hyperkalemia. |
| Potassium Blood Pressure Randomized Trial | Mineralocorticoid receptor antagonists (MRAs) are the cornerstone of the management of heart failure and chronic kidney disease. | 4 | Hirai T (2026) | Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: Clinical Evidence, Pharmacology, and Drug-Drug Interactions for Personalized Management of Hyperkalemia. |
Source documents